Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Carcinoma, Non-Small-Cell Lung 76Squamous Cell Carcinoma of Head and Neck 43Lung Neoplasms 34Urinary Bladder Neoplasms 22Oropharyngeal Neoplasms 22Head and Neck Neoplasms 18Nasopharyngeal Carcinoma 17Carcinoma 15Biliary Tract Neoplasms 15Small Cell Lung Carcinoma 14Uterine Cervical Neoplasms 13Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Squamous Cell Carcinoma 13Cholangiocarcinoma 13Colorectal Neoplasms 12Pancreatic Neoplasms 11Neoplasms 11Carcinoma, Squamous Cell 11Ovarian Neoplasms 10Mouth Neoplasms 9Laryngeal Neoplasms 9Gallbladder Neoplasms 8Endometrial Neoplasms 8Carcinoma, Transitional Cell 8Hypopharyngeal Neoplasms 7Esophageal Neoplasms 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Mesothelioma, Malignant 6

Interventions

Cyclophosphamide 9X-Rays 8Specimen Handling 8Phantoms, Imaging 7fludarabine 6Magnetic Resonance Spectroscopy 6cabozantinib 5Gemcitabine 5Biopsy 5Nuclear Medicine Department, Hospital 4Methotrexate 4Doxorubicin 4fludarabine phosphate 3Ifosfamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2mifamurtide 2larotrectinib 2ivosidenib 2irinotecan sucrosofate 2ensartinib 2atezolizumab 2Vincristine 2Temozolomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Osteosarcoma × Cisplatin × 90 days × Clear all
NCT05691478 2026-06-03

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

National Cancer Institute (NCI)

Phase 2/3 Recruiting
1,122 enrolled
Sarcoma

Osteosarcoma

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
45 enrolled
Sarcoma

Neoplasm Metastasis, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡